Isotonic and isometric responses of blood pressure and heart rate in mild to moderate hypertension with isradipine and propranolol.
The objectives of this study were (a) to evaluate the dose-response effect of isradipine, a dihydropyridine calcium antagonist, on the heart rate and blood pressure of males with mild to moderate hypertension; and (b) to compare these results with those obtained with propranolol, a beta-adrenoceptor blocker, on a matched patient population. Twenty-four patients entered a single-blind study, beginning with a 2-week washout placebo period followed by a forced-titration period. Treadmill and hand-grip tests were also performed. Two weeks were allocated to each stage of the therapy. The end point of the study was normalization of blood pressure with a minimum of side effects. Results and conclusions include the following: both drugs were effective in reducing systolic blood pressure (SBP) and diastolic blood pressure (DBP), but isradipine was more effective in reducing the DBP; isometric exercise can predict accurately the results of the isotonic exercise; the maximum therapeutic effect of propranolol was achieved during the second study-dose level; increases in the isradipine dose were reflected in a proportional reduction of SBP and DBP; and the incidence of side effects is lower among isradipine-treated patients compared to propranolol-treated patients.
Cantor
A
A
Rehabilitation Service, Soroka Medical Center, Beer Sheva, Israel.
Cristal
N
N
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D015444:Exercise; D005080:Exercise Test; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D017275:Isradipine; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D011433:Propranolol / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D016037:Single-Blind Method
D002121:Calcium Channel Blockers; D011725:Pyridines; D011433:Propranolol; D017275:Isradipine